ORCHPHARMA

Order Win: Orchid Pharma Limited won licensing and supply agreement from Laboratorio Libra S.A. Order Value: USD 80 million (approx. over the first 10 years). Completion Timeline: 10 years partnership.

- The Board of Directors approved an enabling resolution to explore fundraising opportunities up to ₹600 crores. - Funds may be raised via equity shares, convertible debentures, QIP, private placement, public issue, or preferential issue. - The proposal is subject to necessary statutory, regulatory, and shareholder approvals.

- Orchid Pharma Limited informed the exchange about the outcome of its board meeting held on October 20, 2026. - The Board approved an enabling resolution to explore fundraising opportunities up to ₹600 crores through equity shares, convertible debentures, QIP, preferential issue, or other permissible modes.

- Trading window closed from October 01, 2026 for Q2 FY2026-27 financial results. - Reopens 48 hours after the declaration of financial results. - Board meeting date to consider and approve results will be intimated separately.